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BRIEF DEFINITIVE REPORT
        Cytotoxic lymphocytes, such as NK cells and 
CD8 T cells, require adhesion molecules to mi-
grate into sites of infection and the tumor micro-
environment and establish tight contact with 
virally infected and tumor cells (  1  ). Moreover, in 
secondary lymphoid organs, adhesion molecules 
facilitate CD8 T cell and NK cell interactions 
with professional APCs, which induce their ac-
tivation, expansion, and diff  erentiation. Adhe-
sion molecules act directly as signaling molecules, 
initiating intracellular pathways that trigger 
activation and adhesiveness of cytotoxic lym-
phocytes. They also act as accessory molecules, 
sustaining cellular contacts that are necessary for 
the TCRs and NK cell receptors to engage their 
cognate ligands and deliver intracellular signals. 
  CD8 T cells and NK cells express multiple 
adhesion molecules. Although several studies 
have addressed the importance of integrins (  1  ), 
attention has recently focused on a novel Ig 
superfamily adhesion molecule called DNAX 
accessory molecule 1 (DNAM-1; also known as 
CD226). In humans, DNAM-1 is normally ex-
pressed on NK cells and CD8 T cells, as well as 
CD4 T cells and monocytes (  2  ). In mice,     40  –
  50% of NK cells and all CD8 T cells constitu-
tively express DNAM-1, whereas CD4 T cells 
express DNAM-1 preferentially upon activation 
(  3  ). DNAM-1 binds to CD155, also known as 
Necl-5 or poliovirus receptor (  4, 5  ). CD155 
is expressed on epithelial cells, endothelial 
cells, and APCs. DNAM-1 also binds CD112 
(Nectin-2), which is found on epithelial cells 
(  4, 5  ). In vitro studies have shown that DNAM-
1 triggers NK cell  –  mediated killing of tumor 
cells expressing CD155 and CD112 (  4, 6  –  10  ). 
DNAM-1 also facilitates NK cell interaction 
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  Natural killer (NK) cells and CD8 T cells require adhesion molecules for migration, activa-
tion, expansion, differentiation, and effector functions. DNAX accessory molecule 1 
(DNAM-1), an adhesion molecule belonging to the immunoglobulin superfamily, promotes 
many of these functions in vitro. However, because NK cells and CD8 T cells express mul-
tiple adhesion molecules, it is unclear whether DNAM-1 has a unique function or is effec-
tively redundant in vivo. To address this question, we generated mice lacking DNAM-1 and 
evaluated DNAM-1  –  defi  cient CD8 T cell and NK cell function in vitro and in vivo. Our 
results demonstrate that CD8 T cells require DNAM-1 for co-stimulation when recognizing 
antigen presented by nonprofessional antigen-presenting cells; in contrast, DNAM-1 is 
dispensable when dendritic cells present the antigen. Similarly, NK cells require DNAM-1 
for the elimination of tumor cells that are comparatively resistant to NK cell  –  mediated 
cytotoxicity caused by the paucity of other NK cell  –  activating ligands. We conclude that 
DNAM-1 serves to extend the range of target cells that can activate CD8 T cell and NK 
cells and, hence, may be essential for immunosurveillance against tumors and/or viruses 
that evade recognition by other activating or accessory molecules. 
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expression of DNAM-1 and evaluated DNAM-1  –  defi  cient 
CD8 T cell and NK cell function in vitro and in vivo. Our re-
sults demonstrate that CD8 T cells require co-stimulation by 
DNAM-1 when the antigen is presented by nonprofessional 
APCs, whereas DNAM-1 is dispensable in the presence of 
DCs. Thus, DNAM-1 can promote CD8 T cell responses to 
tumors expressing CD155 and/or CD112. In an analogous 
fashion, NK cells require DNAM-1 for elimination of tumor 
cells that are relatively resistant to NK cell  –  mediated cytotoxic-
ity caused by the absence of other NK cell  –  activating ligands. 
In brief, DNAM-1 broadens the range of target cells that can 
activate CD8 T cells and NK cells and, hence, it may be critical 
for immunosurveillance of tumors and/or viruses that escape 
recognition by other activating or accessory molecules. 
    RESULTS AND DISCUSSION   
  Normal development of DNAM-1  –  defi  cient mice 
  To generate DNAM-1      /      mice, we designed a targeting 
vector to replace exons two and three, encoding the start site 
and the fi  rst 129 amino acids of DNAM-1 with an MC1-neo  r   
with subsets of DCs that express CD155 (  11  ). Moreover, 
DNAM-1 promotes co-stimulation of CD4 and CD8 T cells 
(  3, 12, 13  ) and mediates adhesion of monocytes to endothelial 
cells facilitating transendothelial migration (  14  ). DNAM-1 
physically associates with the integrin lymphocyte function-
associated antigen 1 (    L    2) and modulates its activation and 
capacity to bind intercellular adhesion molecule 1 (  2, 15  ). 
Mechanistically, DNAM-1 recruits actin-binding proteins 
such as Discs-large and 4.1G, which rearrange actin cytoskel-
eton, promoting clustering of lymphocyte function-associated 
antigen 1 and formation of an adhesive complex that polarizes 
lymphocytes toward other cells (  16  ). 
  In summary, DNAM-1 appears to contribute to multiple 
innate and adaptive responses, which include (a) leukocyte mi-
gration; (b) activation, expansion, and diff  erentiation of CD8 
T cells and CD4 T cells; and (c) eff  ector responses of T cells and 
NK cells. However, because cytotoxic lymphocytes express 
multiple adhesion molecules, it is diffi   cult to determine whether 
DNAM-1 plays a unique role in these functions or is redun-
dant. To address this question, we generated mice lacking 
    Figure 1.         DNAM-1 augments CD8 T cell division in response to superantigen.   (A and B) FACS analysis of CFSE dilution 72 h after (A) WT or 
(B) DNAM-1     /     T cells were co-cultured with A20 cells or A20 cells expressing mCD155 in the presence of the indicated concentrations of SEB. The per-
centage of undivided CD8 T cells is indicated. (left) Two control panels show the CFSE content of T cells incubated with unpulsed APCs. (C) Percentage 
of dividing CD8 T cells stimulated by A20 or A20-mCD155 at graded concentrations of SEB. (D) Proliferation of WT or DNAM-1     /     T cells stimulated by 
A20 or A20-mCD155 in the presence of graded concentrations of SEB measured by [  3  H]thymidine incorporation. Results are means   ±   SEM. **, P   <   0.01. 
(E) Expression of MHC class II and mCD155 on control and CD155-transfected A20 B cell lymphoma.     JEM VOL. 205, December 22, 2008  2967
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signal for CD8 T cell proliferation when T cells are stimulated 
by nonprofessional APCs. 
  DNAM-1 co-stimulation is not essential for CD8 T cell 
stimulation by professional APCs 
  We then asked whether DNAM-1  –  CD155 interaction contrib-
utes to the priming and expansion of CD8 T cells by professional 
APCs. To evaluate this possibility, we fi  rst determined whether 
CD155 is expressed on mouse DCs, as has been shown for 
human monocyte-derived DCs (  11  ). Consequently, we estab-
lished a mCD155-specifi  c antibody (Fig. S1) and stained imma-
ture and activated bone marrow  –  derived DCs (BMDCs). 
BMDCs constitutively expressed mCD155 and the expression 
level was further augmented by stimulation with Toll-like 
receptor agonists, including LPS, poly I:C, zymosan, and CpG 
oligonucleotides (  Fig. 3 A  ).   To determine whether mCD155 is 
expressed on primary DCs involved in antigen presentation, we 
applied a mixture of a green fl  uorescent cell tracker and a mild 
irritant to the ears of mice. We extracted draining cervical lymph 
nodes (CLNs) 48 h later and examined DC by fl  ow cytometry. 
mCD155 was selectively expressed on cell tracker  +   DCs that had 
migrated from the skin (  Fig. 3 B  ). DCs that migrate to the CLNs 
at this time point are mainly dermal DCs, whereas Langerhans 
cells reach the CLNs at later time points (  18  ). Thus, mCD155 is 
expressed on dermal DCs that migrate into the lymph nodes. In 
contrast, we were unable to detect mCD155 expression on pri-
mary spleen mouse DCs (unpublished data). We conclude that 
mCD155 is expressed on primary DCs that migrate from the 
periphery into the lymph nodes and, therefore, may potentially 
contribute to DC-mediated priming of T cell responses. 
  To evaluate this possibility, we stimulated WT and 
DNAM-1      /      CD8 OT-1 cells with BMDCs that had been 
gene fl  anked by loxP sites (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20081752/DC1). One targeted 
E14.1 (129P2/OlaHsd) embryonic stem cell was injected into 
C57BL/6 blastocysts, and resulting chimeras were bred to 
C57BL/6 mice expressing a Cre transgene under the CMV 
promoter to delete the MC1-neo  r   gene. The DNAM-1 dele-
tion was then backcrossed onto a C57BL/6 background. 
Homozygote DNAM-1      /      mice were obtained at expected 
frequencies from intercrosses of heterozygote mice. DNAM-
1      /      mice were phenotypically normal and healthy, and devel-
oped no gross abnormalities up to 1 yr of age. Flow cytometric 
analysis of DNAM-1      /      mice did not reveal major diff  er-
ences in the lymphoid cell populations (NK cells, CD8 T cells, 
CD4 T cells, DCs, plasmacytoid DCs, and B cells) in the 
spleen, thymus, peripheral blood, and lymph nodes or in bone 
marrow precursor populations (Figs. S1  –  S3; and not depicted). 
Therefore, DNAM-1 appears to be dispensable for develop-
ment, including that of the immune system. Additionally, lack 
of DNAM-1 did not result in any compensatory change in 
the expression of CD96, the alternative lymphocyte receptor 
for CD155 (Fig. S1) (  7, 17  ). 
  DNAM-1 is essential for CD8 T cell responses 
to nonprofessional APCs 
  To assess the co-stimulatory function of DNAM-1 on CD8 
T cells, we isolated T cells from WT and DNAM-1      /      mice, 
labeled them with CFSE, and stimulated them in vitro with 
APCs pulsed with graded doses of staphylococcal enterotoxin 
B (SEB) superantigen. As APCs, we used the B cell line A20, 
which expresses MHC class II, or A20 cells transfected with 
murine CD155 (mCD155;   Fig. 1 E  ).   After 72 h, we har-
vested cells and evaluated CD8 T cell division. The percent-
age of dividing WT CD8 T cells was signifi  cantly higher when 
T cells were stimulated with A20-mCD155 rather than A20 
parental cells (  Fig. 1, A and C  ). In contrast, CD155 had a rel-
atively minor eff   ect on the proliferation of DNAM-1      /      
CD8 T cells; the percentage of dividing DNAM-1      /      CD8 
T cells was only slightly higher when SEB was presented by 
A20-mCD155 cells (  Fig. 1, B and C  ). Similar results were 
obtained when the CD8 T cell proliferative response to SEB 
was measured by thymidine incorporation (  Fig. 1 D  ). These 
data demonstrate a clear role of DNAM-1 in priming and ex-
pansion of CD8 T cells in response to a superantigen presented 
by B cells. 
  To evaluate the impact of DNAM-1 on CD8 T cell 
responses to antigens, we crossed OT-1 transgenic mice to 
DNAM-1      /      mice. We then evaluated the proliferation of 
purifi  ed WT and DNAM-1      /      CD8 transgenic T cells stimu-
lated with the T cell lymphoma cell line EL-4 transfected with 
mCD155 and pulsed with OVA peptide 257  –  264 (  Fig. 2 A  ).   
In this setting, OT-1 CD8 T cells lacking DNAM-1 prolifer-
ated less effi   ciently than WT OT-1 cells and also failed to 
become activated, as demonstrated by a lack of increase in size 
and granule content detected in forward scatter (FSC)/side 
scatter (SSC) profi  les (  Fig. 2 B  ). Collectively, these data fi  rmly 
establish that DNAM-1 provides an important co-stimulatory 
    Figure 2.         DNAM-1 promotes CD8 T cell proliferation in response to 
antigen presented by nonprofessional APCs.   DNAM-1    /     OT-1  transgenic 
CD8 T cells proliferate less effi  ciently than WT OT-1 cells in response to SIIN-
FEKL peptide presented by EL-4 T lymphoma cells expressing mCD155. 
Proliferation was measured (A) by [  3  H]thymidine incorporation or (B) by 
evaluating the increase in SSC and FSC by fl  ow cytometry in blasting cells. 
Dot plot analysis shows stimulation induced by 10 ng/ml SIINFEKL. One rep-
resentative experiment out of three is shown. Results in A are means   ±   SEM.     2968 REQUIREMENT OF DNAM-1 FOR NK CELL AND CD8 T CELL ACTIVATION IN VIVO   | Gilfi  llan et al. 
defi  ciency had no marked impact on CD8 T cell priming. In 
contrast, fewer IFN-      –  secreting T cells were evident in lymph 
nodes from the DNAM-1      /      mice after restimulation with 
EL-4  –  mCD155 (  Fig. 3 D  ), corroborating a role for DNAM-1 
in promoting CD8 T cell activation and function in response 
to stimulation by nonprofessional APCs. 
  NK cells require DNAM-1 to eliminate targets resistant 
to cytotoxicity 
  Because CD155 is expressed on many tumor cells, DNAM-1 
has been implicated as a major trigger for NK cell antitumor 
activity (  4, 6  –  10  ). However, NK cells express additional recep-
tors that mediate antitumor activity. NKG2D triggers NK cell 
surveillance against tumor cells expressing stress-induced MHC 
class I  –  related ligands such as MIC-A, MIC-B, and UL16-
binding protein in humans, and Rae1, H60, and Mult1 in 
mice (  19  –  21  ). Natural cytotoxicity receptors, such as NKp46, 
NKp44, and NKp30, have also been shown to mediate an 
pulsed with OVA peptide 257  –  264. We used immature BMDCs 
and mature BMDCs activated with a CpG oligonucleotide. 
In contrast to our results obtained using A20 and EL-4 as 
APCs, lack of DNAM-1 had no impact on the capacity of 
OT-1 T cells to proliferate in response to DCs (  Fig. 3 C  ). 
We conclude that co-stimulation by DNAM-1 is not re-
quired when T cells are stimulated by professional APCs, at 
least in vitro. To assess the impact of DNAM-1 defi  ciency 
on the generation of antigen-specifi  c T cells in vivo, we im-
munized WT and DNAM-1      /      mice in the footpad with 
OVA peptide 257  –  264. After 1 wk, we removed draining 
lymph nodes and restimulated all cells in vitro with either 
BMDCs or EL-4  –  mCD155 pulsed with OVA peptide 257  –
  264. The frequency of OVA-specifi  c CD8 T cells was deter-
mined by intracellular staining for IFN-    . No signifi  cant 
diff  erences in the frequency of IFN-      –  secreting T cells was 
observed after restimulation of DNAM-1      /      and WT lymph 
nodes with DCs (unpublished data), indicating that DNAM-1 
    Figure 3.         DC-induced CD8 T cell stimulation is DNAM-1 independent.   (A) BMDCs express of CD155, which is up-regulated by Toll-like receptor  –
  induced DC maturation. (B) Expression of CD155 on CD11c  +   DCs migrating from the periphery to CLNs 48 h after ear painting. A gate was applied on 
SSC/FSC to exclude small lymphocytes. (C) Proliferation of WT and DNAM-1     /     OT-1 in response to immature BMDCs pulsed with OVA for 18 h (left) or 
with OVA for 3 h followed by stimulation with CpG ODN1826 for 7 h (right). Proliferation was evaluated by [  3  H]thymidine incorporation. Results are 
means   ±   SEM. (D) Percentages of CD8 T cells producing IFN-     after in vitro restimulation with EL-4  –  CD155 cells either pulsed or not pulsed with OVA 
peptide 257  –  264. Mice (six per group) were tested 8 d after footpad immunization. Horizontal bars represent means. *, P   <   0.05.   JEM VOL. 205, December 22, 2008  2969
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important role in antitumor activity (  22  ). The relative contri-
bution of DNAM-1 versus other receptors has not been ad-
dressed in vivo. We fi  rst examined the cytotoxic ability of 
purifi  ed DNAM-1      /      and WT NK cells cultured with IL-2 
to kill target cells in vitro. As target cells, we chose YAC-1 and 
B16F10. YAC-1 expresses the ligands for NKG2D, whereas 
B16F10 does not (  23, 24  ); both targets express ligands for 
DNAM-1 (  Fig. 4 A  ).   We found that IL-2  –  cultured NK cells 
effi   ciently killed YAC-1 cells whether or not they expressed 
DNAM-1 (  Fig. 4 B  ). In contrast, although WT NK cells were 
capable of killing B16F10 tumors, DNAM-1      /      NK cells did 
not appreciably kill this tumor target (  Fig. 4 C  ). Interestingly, 
DNAM-1      /      OT-1 CD8 T cells killed B16 cells pulsed with 
OVA peptide 257  –  264 less eff  ectively than WT OT-1 CD8 
T cells (  Fig. 4 D  ), indicating that DNAM-1 may contribute to 
the cytotoxic function of both innate and adaptive lymphocytes. 
  To determine whether DNAM-1 contributes to NK 
cell  –  mediated surveillance against tumors in vivo, we initially 
chose to examine the B16F10 experimental metastases model. 
Tumor cells were injected i.v. and lung metastases were 
counted 2 wk after inoculation. At lower tumor doses (5   ×   
10  4   and 10  5   cells), DNAM-1      /      mice had signifi  cantly higher 
numbers of B16F10 lung metastases than did WT mice (  Fig. 
5 A  ).   At the highest dose of B16F10 (2   ×   10  5   cells), DNAM-
1 defi  ciency had no eff  ect, suggesting that the host response 
was completely overwhelmed at this dose. The rejection of 
B16F10 was entirely NK cell dependent, as illustrated by the 
lack of rejection of metastases after depletion of NK cells by 
the anti-asGM1 antibody (  Fig. 5 A  ). Interestingly, the aug-
mented tumor growth caused by DNAM-1 defi  ciency was 
not as severe as that caused by NK cell depletion, indicating 
that DNAM-1  –  CD155 interaction is not the only mecha-
nism by which NK cells mediate rejection of B16F10. Accord-
ingly, we observed that only a subset of     50% of NK cells 
expresses DNAM-1 (Fig. S1). Similar results were obtained 
in another experimental metastases model based on the injec-
tion of the mouse prostate carcinoma, RM-1, that also expresses 
mCD155 (unpublished data). At all tumor doses inoculated 
(10  3  , 5   ×   10  3  , and 10  4   cells), DNAM-1      /      mice had signifi  -
cantly higher numbers of RM-1 lung metastases than WT 
mice (  Fig. 5 B  ), although, again, mice depleted of NK cells 
had the highest numbers of metastases. Consistent with the 
metastases data, accelerated tumor growth was also observed 
after s.c. injection of B16F10 in DNAM-1      /      mice as com-
pared with WT mice (  Fig. 5 C  ). These results corroborate 
the increased susceptibility of DNAM-1  –  defi  cient mice to 
tumors because of the reduced function of NK cells. 
  DNAM-1 promotes CD8 T cell  –  mediated tumor rejection 
  To determine whether DNAM-1 contributes to CD8 T cell  –
  mediated tumor immunosurveillance, we used a tumor model 
based on inoculation of a colon carcinoma cell line, MC38, 
that has been transfected with OVA (MC38-OVA). We chose 
MC38-OVA because this tumor cell line expresses ligands for 
DNAM-1, CD112, and CD155 (  Fig. 5 D  ). In addition, our 
initial studies demonstrated that s.c. inoculation of MC38-
    Figure 4.         Lack of DNAM-1 impairs NK cell and CD8 T cell cyto-
toxicity.   (A) Differential expression of DNAM-1 ligands on B16F10 and 
YAC cells. B16F10 and YAC-1 cells were analyzed for the expression of 
CD155 and CD112 by fl  ow cytometry. Open histograms represent stain-
ing with the respective antibody, whereas shaded histograms show 
isotype staining. These data represent three independent experiments. 
(B and C) Lack of DNAM-1 affects NK cell  –  mediated death of tumor 
cells lacking NKG2D ligands. IL-2  –  activated purifi  ed NK cells were 
tested for cytotoxic activity against (B) YAC and (C) B16F10 targets in a 
standard 4-h   51  Cr release assay. Each data point is the mean   ±   SEM of 
two independent experiments done in triplicate for each effector/target 
ratio. (D) Reduced killing of B16 cells pulsed with OVA peptide by 
DNAM-1     /     CD8 T cells. Splenocytes from OT-1 transgenic mice were 
stimulated with OVA peptide 257  –  264 and cultured in vitro for 15 d in 
the presence of 20 U/ml IL-2. Antigen-specifi  c cytotoxicity was assessed 
using B16 cells, either pulsed or not pulsed with 100 pg/ml OVA peptide 
257  –  264. Naive WT OT-1 CD8  +   T cells did not kill peptide-pulsed target 
cells. The data represent two independent experiments.     2970 REQUIREMENT OF DNAM-1 FOR NK CELL AND CD8 T CELL ACTIVATION IN VIVO   | Gilfi  llan et al. 
are critical for MC38-OVA tumor rejection. MC38-OVA grew 
similarly for the fi  rst 5 d after injection into DNAM-1      /      
and WT mice. Subsequently, however, DNAM-1      /      mice 
OVA induces marked tumor growth in WT mice depleted of 
CD8 T cells and RAG1      /      mice in comparison to control Ig  –
  treated WT mice (  Fig. 5 E  ), which indicates that CD8 T cells 
    Figure 5.         Reduced NK cell  –   and CD8 T cell  –  mediated suppression of tumors in DNAM-1      /      mice.   (A and B) B6 WT and DNAM-1     /     mice  were 
challenged i.v. with various doses (as indicated) of either (A) B16F10 or (B) RM-1, as described in Materials and methods. Lungs were harvested on day 14 
and fi  xed in Bouin  ’  s solution, and tumor colonies were counted under a dissecting microscope. Data are depicted as mean tumor colonies   ±   SEM  ( n   = 
5  –  14 mice for each dose/group). Statistical differences between WT and DNAM-1     /     mice are depicted by asterisks (P   <   0.05 using the Mann-Whitney 
test). (C) WT and DNAM-1     /     mice were injected with 5   ×   10  4   B16F10 tumor cells s.c., and tumor growth was monitored at least every second day using 
a caliper square to determine the product of two perpendicular tumor diameters. Some groups of WT mice were depleted of CD8 T cells or NK cells, as 
described in Materials and methods. Results were recorded as the means   ±   SEM of fi  ve mice and are representative of two to four independent experi-
ments. Statistical differences between WT + cIg and DNAM-1     /     mice are depicted by an asterisk (P   <   0.05 using the Mann-Whitney test). (D) Expression 
of CD155 and CD112 on MC38-OVA cells as assessed by fl  ow cytometry. Open histograms represent staining with the respective antibody, whereas 
shaded histograms show isotype staining. (E) WT or RAG1     /     mice were injected with 10  6   MC38-OVA tumor cells s.c., and tumor growth was monitored 
as described in C. Some groups of WT mice were depleted of CD8 T cells. (F) WT and DNAM-1     /     mice were injected with 10  6   MC38-OVA tumor cells s.c., 
and tumor growth was monitored as described in C. Results were recorded as the means   ±   SEM of fi  ve (E) or nine (F) mice.     JEM VOL. 205, December 22, 2008  2971
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How DNAM-1 infl  uences CD4 T cell and perhaps T reg cell 
responses remains an open question. 
  In conclusion, this report provides the fi  rst demonstration 
that DNAM-1 promotes CD8 T cell co-stimulation and NK 
cell responses in vivo, broadening the spectrum of target cells 
that are eff  ectively recognized. It has been shown that human 
CMV reduces expression of CD155 in infected cells through 
UL141 (  29  ). Moreover, some tumors overexpress CD155 
and release it as a soluble molecule (  30  ), possibly to block 
DNAM-1 and prevent recognition of tumor cells. These 
mechanisms of evasion underscore the potential importance 
of DNAM-1  –  CD155 interactions in immunosurveillance 
against tumors and/or viral infections, particularly those that 
are weakly immunogenic because they do not engage major 
activating or accessory molecules. 
  MATERIALS AND METHODS 
  DNAM-1      /       mice.     A targeting vector was designed to replace exons two 
and three (encoding the start site and fi  rst 129 amino acids) of DNAM-1 with 
an MC1-neo  r   gene fl  anked by loxP sites (Fig. S1). The construct was linear-
ized and electroporated into E14.1 (129P2/OlaHsd) embryonic stem cells; 
747 clones from two independent experiments were expanded and screened 
by Southern blotting using an external probe. One targeted clone was identi-
fi  ed and confi  rmed using multiple restriction enzyme digests and external and 
internal probes. The clone was injected into C57BL/6 blastocysts, and result-
ing chimeras were bred to C57BL/6 mice expressing a Cre transgene under 
the CMV promoter to delete the MC1-neo  r   gene. Germline transmission 
was assessed by coat color and the presence of the DNAM-1 mutation by 
PCR. The DNAM-1 deletion was backcrossed onto a C57BL/6 background, 
facilitated by a genome-wide screening of polymorphic microsatellite mark-
ers at 10-centiMorgan intervals at each generation (performed by the Rheu-
matic Disease Core Center  ’  s Speed Congenics Laboratory, Washington 
University School of Medicine). A 96% C57BL/6 male (B6N4) was identi-
fi  ed for further backcrossing; B6N6 heterozygotes were intercrossed to gen-
erate the DNAM-1      /      mice used for this study. C57BL/6 WT, and 
RAG1      /      and OT-1 transgenic mice (obtained from the Jackson Laboratory) 
were bred and maintained at an Association for Assessment and Accreditation 
of Laboratory Animal Care  –  approved facility at Washington University 
School of Medicine and/or the Peter MacCallum Cancer Centre. All experi-
ments were approved by the Washington University Animal Care Commit-
tee and the Peter MacCallum Animal Experimentation Ethics Committee. 
  Cell lines.     RM-1, B16F10, YAC-1, MC38-OVA, RMA-S, A20, and 
EL-4 cells were maintained in RPMI 1640 supplemented with 10% FCS. 
Stable transfectants of mCD155 were generated by electroporation of 
mCD155 cDNA. Positive cells were purifi   ed by FACS sorting. The 
MC38-OVA line was generated by retrovirally infecting the MC38 paren-
tal line with a pMIG/MSCV-IRES-eGFP plasmid-encoding membrane-
bound OVA (provided by J. Villadangos, Walter and Eliza Hall Institute 
for Medical Research, Parkville, Australia). 
  Antibodies and reagents.     We generated the mAb 480.1 anti  –  mouse 
DNAM-1 (mDNAM-1) or mAb 3.1 anti  –  mouse CD96 (mCD96) by im-
munizing rats with RBL cells transfected with mDNAM-1 cDNA (RBL  –
  mDNAM-1) or mouse CD96 cDNA (RBL-mCD96) and selecting 
hybridomas that reacted with 293  –  mDNAM-1 or 293-mCD96 transfectants 
but not with untransfected 293 cells. To generate the mAb 4.24 to mCD155, 
we immunized rats with a recombinant protein consisting of the mCD155 
extracellular region fused to human Fc and selected hybridomas that reacted 
with RMA-S  –  mCD155 transfectants but not with untransfected RMA-S 
cells. Anti-asGM1 for depletion of NK cells was obtained from Wako 
Chemicals USA, Inc., and anti-CD8 mAb (53.6.7) was produced in our lab-
oratory. Some groups of B6 mice were depleted of CD8  +   T lymphocytes or 
failed to reject the tumor as compared with WT control 
(  Fig. 5 F  ). We conclude that DNAM-1 contributes to CD8 T 
cell  –  mediated tumor immunosurveillance, most likely by co-
stimulating CD8 T cells. 
  Concluding remarks 
  This report is the fi   rst describing mice specifi  cally  lacking 
DNAM-1 and defi  nitively establishes an in vivo role for 
DNAM-1 during CD8 T cell and NK cell responses. Our re-
sults demonstrate that CD8 T cells require DNAM-1 for effi   -
cient stimulation by APCs that are weakly immunogenic, 
whereas a lack of DNAM-1 has no detectable impact on CD8 
T cell stimulation by DCs. Thus, although DNAM-1 acces-
sory function may be redundant in secondary lymphoid or-
gans, it may be essential in peripheral tissues to promote optimal 
activation and eff  ector functions of CD8 T cells that recognize 
their cognate MHC-peptide antigen on cells with limited ex-
pression of co-stimulatory ligands, such as tumor cells. Intraepi-
thelial lymphocytes,         T cells, and lamina propria lymphocytes 
may also depend on DNAM-1 for co-stimulatory signals from 
epithelial cells expressing CD155. Intraepithelial and          T cells 
have been shown to rely on NKG2D-mediated co-stimulation 
and are in some cases directly activated by NKG2D ligands on 
tumor cells (  25  –  27  ). Given this, DNAM-1 may either aug-
ment or, in some cases, compensate for NKG2D. 
  As indicated by our results with the B16F10 melanoma, 
expression of DNAM-1 enables NK cells to more effi   ciently 
kill tumor cells that are comparatively resistant to NK cell  –
  mediated death because they lack NKG2D ligands. In con-
trast, DNAM-1 is dispensable for NK cell  –  mediated killing 
of highly susceptible targets that express NKG2D ligands, like 
YAC-1. Overall, our data suggest that DNAM-1 may play an 
important role in immunosurveillance against tumors and 
perhaps viral infections that are weakly immunogenic and re-
fractory to NK cell  –  mediated cytotoxicity. Moreover, we 
have shown that DNAM-1 signifi  cantly contributes to CD8 
T cell  –  mediated surveillance against tumor cells expressing 
CD112 and/or CD155. We and others have shown that 
T cells express at least one additional receptor for CD155, 
CD96, which has distinct functional characteristics (  7, 17  ). 
Although it is possible that the lack of DNAM-1 is at least in 
part compensated by CD96, future studies will be necessary 
to determine the relative contributions of these two receptors 
to T cell and NK cell stimulation. 
  Genome-wide analysis of type I diabetes has recently re-
vealed robust association of type I diabetes with a nonsynon-
ymous single nucleotide polymorphism within the   DNAM-1   
gene (  28  ). This observation, together with the observed ex-
pression of both DNAM-1 and CD155 in thymocytes (Fig. 
S3), suggests that DNAM-1  –  CD155 interactions may regu-
late the generation of autoreactive T cells, further emphasiz-
ing the importance of DNAM-1 in the immune response. 
We have shown that DNAM-1 considerably expands the 
range of cells that can activate CD8 T cells and NK cells. 
DNAM-1 is also up-regulated on CD4 T cells after Th1 dif-
ferentiation but is down-regulated on Th0 and Th2 cells (  3  ). 2972 REQUIREMENT OF DNAM-1 FOR NK CELL AND CD8 T CELL ACTIVATION IN VIVO   | Gilfi  llan et al. 
BMDCs (day 6 or 7 of GM-CSF culture). Co-cultures were incubated for 
4 h at 37  °  C. 2   μ  M monensin was added to block cytokine export, and co-cul-
tures were incubated overnight. Cells were surface stained with Fc receptor  –
  blocking mAb 2.4G2, followed by anti-CD8      –  FITC (BD). To prepare for 
intracellular staining, cells were fi  xed in 2% paraformaldehyde (Sigma-
Aldrich) and permeablilized in 0.5% saponin buff  er. Cells were then stained 
with anti  –  IFN-      –  allophycocyanin (BD) and analyzed by fl  ow cytometry. 
  NK cell in vitro assays.     Splenocyte suspensions were prepared as described 
above. For purifi  cation of NK cells by MACS, splenocytes were incubated 
with the NK cell isolation kit (Miltenyi Biotec), and cells were sorted by au-
toMACS (Miltenyi Biotec). NK cell media consisted of RPMI 1640 con-
taining 10% FCS,     -2ME, nonessential amino acids, sodium pyruvate,   
l-  glutamine, and penicillin/streptomycin. NK cells were expanded in NK 
cell media containing 1,000 U/ml IL-2 for 5 d. Cytotoxicity was assessed by 
standard 4-h   51  Cr release assays. 
  In vivo tumor assays.     For lung metastasis assays, single-cell suspensions of 
B16F10 or RM-1 were prepared in PBS, and from 10  3   to 2   ×   10  5   cells were 
injected i.v. in the tail vein of recipient mice. Lungs were harvested on day 
14 and fi  xed in Bouin  ’  s solution, and tumor nodules were counted with the 
aid of a dissection microscope (model SZX7; Olympus). For s.c. tumor as-
says, mice were injected with various doses of B16F10 or MC38-OVA s.c., 
and tumor growth was monitored at least every second day using a caliper 
square to determine the product of two perpendicular tumor diameters. 
  Statistical analysis.     Statistical signifi  cance was assessed through the use of 
the Mann-Whitney rank sum test, as appropriate. 
  Online supplemental material.     Fig. S1 shows the generation of DNAM1      /      
mice and of anti-mCD155 and -mDNAM1 antibodies. Fig. S2 shows NK cell 
percentages and maturation in WT and DNAM1      /      mice. Fig. S3 shows thy-
mic T cell subsets in WT and DNAM1      /      mice. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20081752/DC1. 
  We thank Mike White for blastocyst injections and the Rheumatic Disease Core 
Center  ’  s Speed Congenics Laboratory at Washington University School of Medicine 
for high density microsatellite mapping. 
  This work was supported by National Institutes of Health grant R01AI056139-05 
and Juvenile Diabetes Research Foundation grant 24-2008-938. We thank the 
National Health and Medical Research Council of Australia for the support of program 
grant 454569, a Senior Principal Research Fellowship (to M.J. Smyth), a Doherty 
Fellowship (to D.M. Andrews), and a CJ Martin Fellowship (to N.M. Haynes), as well as 
the Leukaemia Foundation of Australia for a research scholarship (to C.J. Chan). 
  The authors have no confl  icting fi  nancial interests. 
Submitted:   7 August 2008 
Accepted:   30 October 2008 
  REFERENCES 
       1  .   Bryceson  ,   Y.T.  ,   M.E.     March  ,   H.G.     Ljunggren  , and   E.O.     Long  .   2006  . 
  Activation, coactivation, and costimulation of resting human natural 
killer cells.       Immunol. Rev.       214  :  73    –    91  .    
       2  .   Shibuya  ,   A.  ,   D.     Campbell  ,   C.     Hannum  ,   H.     Yssel  ,   K.     Franz-Bacon  ,   T.   
  McClanahan  ,   T.     Kitamura  ,   J.     Nicholl  ,   G.R.     Sutherland  ,   L.L.     Lanier  , 
and   J.H.     Phillips  .   1996  .   DNAM-1, a novel adhesion molecule involved 
in the cytolytic function of T lymphocytes.       Immunity      .     4  :  573    –    581  .    
       3  .   Dardalhon  ,   V.  ,   A.S.     Schubart  ,   J.     Reddy  ,   J.H.     Meyers  ,   L.     Monney  , 
  C.A.     Sabatos  ,   R.     Ahuja  ,   K.     Nguyen  ,   G.J.     Freeman  ,   E.A.     Greenfi  eld  , 
  et al  .   2005  .   CD226 is specifi   cally expressed on the surface of Th1 
cells and regulates their expansion and eff  ector functions.       J. Immunol.     
  175  :  1558    –    1565  .   
       4  .   Bottino  ,   C.  ,   R.     Castriconi  ,   D.     Pende  ,   P.     Rivera  ,   M.     Nanni  ,   B.   
  Carnemolla  ,   C.     Cantoni  ,   J.     Grassi  ,   S.     Marcenaro  ,   N.     Reymond  ,   et al  . 
  2003  .   Identifi  cation of PVR (CD155) and Nectin-2 (CD112) as cell 
surface ligands for the human DNAM-1 (CD226) activating molecule.   
    J. Exp. Med.       198  :  557    –    567  .    
NK cells in vivo by treatment with 100   μ  g anti-CD8 mAb or anti-asGM1 on 
days     1, 0 (day of i.v. tumor inoculation), and 7. These schedules eff  ectively 
deplete T cell or NK cell subsets, as assessed by analysis using FITC-labeled 
mAbs. IL-2 was a gift from Novartis. 
  Cell preparations and FACS analysis.     Single-cell suspensions were pre-
pared from lymph nodes and spleens and depleted of erythrocytes by ammo-
nium chloride lysis. Lung lymphocytes were enriched in a Percoll (GE 
Healthcare) density gradient (45 and 67.5%) at 800 g for 15 min followed by 
ammonium chloride lysis. Cells were stained with anti-NK1.1  –  PE (PK136), 
-TCR          –  PECy5.5 (H57-597), -CD27  –  allophycocyanin (Lg.7F9), and 
-CD11b  –  FITC (M1/70). All antibodies were from eBioscience. Dead cells 
were excluded with 1   μ  g/ml fl  uorogold (Sigma-Aldrich) in the fi  nal wash. 
Cells were acquired on an LSR-II (BD). Analysis was performed using 
FlowJo software (Tree Star, Inc.). YAC-1, B16F10, RM-1, and MC38-
OVA tumor cells were stained with biotinylated anti-mCD155 (clone 4.24) 
and purifi  ed anti-CD112 (clone 502-57; Abcam), followed by streptavidin-
PE (eBioscience) and anti  –  rat  –  PE (Invitrogen), respectively. Cell acquisition 
and analyses were performed as described above. In some experiments, sple-
nocytes or thymocytes were treated with Fc block (HB-197; American Type 
Culture Collection) and were stained with mAb 480.1 and anti-CD4, -CD8, 
-CD3, -NK1.1, -CD25, and -CD44 (all from BD). Samples were processed 
on a FACSCalibur and analyzed with CellQuest software (both from BD). 
  Stimulation with SEB.     Total T cells were purifi  ed from spleens of WT and 
DNAM-1      /      mice by positive selection with CD5 microbeads (Miltenyi Bio-
tec). Contamination with CD5  +   B cells was always   <  3% of the total cells re-
covered. Percentages of TCRV    3, V    7, and V    8 within the CD4 and CD8 
T cell compartments were always comparable in WT and DNAM-1      /      mice, 
as assessed by staining for CD4, CD8, and TCRV    3, V    7, and V    8. A20 and 
mCD155-A20 cells were irradiated (11,000 rads) and pulsed for 4 h with serial 
dilutions of SEB (Toxin Technology Inc.). Cells were extensively washed and 
incubated with T cells labeled with CFSE (Invitrogen). After 72 h, cells were 
stained for CD4 and CD8 and analyzed by fl  ow cytometry. In some experi-
ments, cell proliferation was measured by [  3  H]thymidine incorporation. 
  Antigen stimulation.     OT-1 transgenic CD8 T cells were enriched from 
spleens of WT and DNAM-1      /      mice by negative selection with the CD8 
T cell isolation kit (Miltenyi Biotec). Purity was monitored by staining with 
OVA  257-264   tetramers (Beckman Coulter) and was always found to be   >  90%. 
EL-4 (American Type Culture Collection) and EL-4  –  mCD155 were irradi-
ated (6,000 rads) and pulsed with SIINFEKL peptide (Bachem) for 3 h. Cells 
were extensively washed and incubated with purifi  ed OT-1 transgenic CD8 
T cells for 72 h. Cell proliferation was measured by standard [  3  H]thymidine 
incorporation. Cell blasting was monitored by fl  ow cytometry by recording 
changes in FSC/SSC. 
  In vitro and in vivo analyses of DCs.     Bone marrow cells were cultured 
with GM-CSF and analyzed at day 7 for expression of CD11c, mCD155, 
and CD86. Cells were challenged with 20   μ  g/ml poly I:C (InvivoGen), 
1   μ  g/ml zymosan (Sigma-Aldrich), 6   μ  M CpG 1826 (QIAGEN), and 100 
ng/ml LPS (Ultrapure LPS from   Escherichia coli  ; List Biological Laborato-
ries). Primary migrating DCs were visualized by painting ears of mice with 
CellTracker Green CMFDA (Invitrogen) dissolved in a mixture of acetone 
and dibutyl phthalate, as a source of irritation. CLNs were analyzed 48 h 
later by fl  ow cytometry. 
  Detection of OVA-specifi  c CD8 T cells in vivo.     WT and DNAM-1  –
  defi  cient mice were immunized s.c. in the footpad with CFA and 100 nmol 
OVA peptide 257  –  264 (SIINFEKL). On day 7 or 8, mice were killed and 
popliteal lymph nodes were extracted. Lymph nodes were disrupted by scrap-
ing and were passed over 70-  μ  m nylon cell strainers to make single-cell sus-
pensions. 1.5 million lymph node cells were co-cultured in 24-well plates 
with 5   ×   10  5   APCs either pulsed for 4 h with 1   μ  M SIINFEKL or left un-
pulsed. Two types of APCs were used: EL-4 cells transfected with CD155 or JEM VOL. 205, December 22, 2008  2973
BRIEF DEFINITIVE REPORT
       5  .   Tahara-Hanaoka  ,   S.  ,   K.     Shibuya  ,   Y.     Onoda  ,   H.     Zhang  ,   S.     Yamazaki  , 
  A.     Miyamoto  ,   S.     Honda  ,   L.L.     Lanier  , and   A.     Shibuya  .   2004  .   Functional 
characterization of DNAM-1 (CD226) interaction with its ligands PVR 
(CD155) and nectin-2 (PRR-2/CD112).       Int. Immunol.       16  :  533    –    538  .    
       6  .   Castriconi  ,   R.  ,   A.     Dondero  ,   M.V.     Corrias  ,   E.     Lanino  ,   D.     Pende  ,   L.   
  Moretta  ,   C.     Bottino  , and   A.     Moretta  .   2004  .   Natural killer cell-mediated 
killing of freshly isolated neuroblastoma cells: critical role of DNAX 
accessory molecule-1-poliovirus receptor interaction.       Cancer Res.       64  : 
9180    –    9184  .    
       7  .   Fuchs  ,   A.  ,   M.     Cella  ,   E.     Giurisato  ,   A.S.     Shaw  , and   M.     Colonna  .   2004  . 
  Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by inter-
acting with the poliovirus receptor (CD155).       J. Immunol.       172  :  3994    –    3998  .   
       8  .   Pende  ,   D.  ,   C.     Bottino  ,   R.     Castriconi  ,   C.     Cantoni  ,   S.     Marcenaro  ,   P.   
  Rivera  ,   G.M.     Spaggiari  ,   A.     Dondero  ,   B.     Carnemolla  ,   N.     Reymond  , 
  et al  .   2005  .   PVR (CD155) and Nectin-2 (CD112) as ligands of the human 
DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis.   
    Mol. Immunol.       42  :  463    –    469  .    
       9  .   Tahara-Hanaoka  ,   S.  ,   K.     Shibuya  ,   H.     Kai  ,   A.     Miyamoto  ,   Y.     Morikawa  , 
  N.     Ohkochi  ,   S.     Honda  , and   A.     Shibuya  .   2006  .   Tumor rejection by the 
poliovirus receptor family ligands of the DNAM-1 (CD226) receptor.   
    Blood      .     107  :  1491    –    1496  .    
        10  .   El-Sherbiny  ,   Y.M.  ,   J.L.     Meade  ,   T.D.     Holmes  ,   D.     McGonagle  ,   S.L.   
  Mackie  ,   A.W.     Morgan  ,   G.     Cook  ,   S.     Feyler  ,   S.J.     Richards  ,   F.E.     Davies  , 
  et al  .   2007  .   The requirement for DNAM-1, NKG2D, and NKp46 in 
the natural killer cell-mediated killing of myeloma cells.       Cancer Res.     
  67  :  8444    –    8449  .    
        11  .   Pende  ,   D.  ,   R.     Castriconi  ,   P.     Romagnani  ,   G.M.     Spaggiari  ,   S.     Marcenaro  , 
  A.     Dondero  ,   E.     Lazzeri  ,   L.     Lasagni  ,   S.     Martini  ,   P.     Rivera  ,   et al  .   2006  . 
  Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus 
receptor (CD155), on dendritic cells: relevance for natural killer-den-
dritic cell interaction.       Blood      .     107  :  2030    –    2036  .    
        12  .   Shibuya  ,   K.  ,   J.     Shirakawa  ,   T.     Kameyama  ,   S.     Honda  ,   S.     Tahara-Hanaoka  , 
  A.     Miyamoto  ,   M.     Onodera  ,   T.     Sumida  ,   H.     Nakauchi  ,   H.     Miyoshi  , and 
  A.     Shibuya  .   2003  .   CD226 (DNAM-1) is involved in lymphocyte func-
tion  –  associated antigen 1 costimulatory signal for naive T cell diff  eren-
tiation and proliferation.       J. Exp. Med.       198  :  1829    –    1839  .    
        13  .   Della Chiesa  ,   M.  ,   C.     Romagnani  ,   A.     Thiel  ,   L.     Moretta  , and   A.     Moretta  . 
  2006  .   Multidirectional interactions are bridging human NK cells with 
plasmacytoid and monocyte-derived dendritic cells during innate im-
mune responses.       Blood      .     108  :  3851    –    3858  .    
        14  .   Reymond  ,   N.  ,   A.M.     Imbert  ,   E.     Devilard  ,   S.     Fabre  ,   C.     Chabannon  ,   L.   
  Xerri  ,   C.     Farnarier  ,   C.     Cantoni  ,   C.     Bottino  ,   A.     Moretta  ,   et al  .   2004  . 
  DNAM-1 and PVR regulate monocyte migration through endothelial 
junctions.       J. Exp. Med.       199  :  1331    –    1341  .    
        15  .   Shibuya  ,   K.  ,   L.L.     Lanier  ,   J.H.     Phillips  ,   H.D.     Ochs  ,   K.     Shimizu  ,   E.   
  Nakayama  ,   H.     Nakauchi  , and   A.     Shibuya  .   1999  .   Physical and functional 
association of LFA-1 with DNAM-1 adhesion molecule.       Immunity      .   
  11  :  615    –    623  .    
        16  .   Ralston  ,   K.J.  ,   S.L.     Hird  ,   X.     Zhang  ,   J.L.     Scott  ,   B.     Jin  ,   R.F.     Thorne  ,   M.C.   
  Berndt  ,   A.W.     Boyd  , and   G.F.     Burns  .   2004  .   The LFA-1-associated mole-
cule PTA-1 (CD226) on T cells forms a dynamic molecular complex with 
protein 4.1G and human discs large.       J. Biol. Chem.       279  :  33816    –    33828  .    
        17  .   Seth  ,   S.  ,   M.K.     Maier  ,   Q.     Qiu  ,   I.     Ravens  ,   E.     Kremmer  ,   R.     Forster  , and 
  G.     Bernhardt  .   2007  .   The murine pan T cell marker CD96 is an adhe-
sion receptor for CD155 and nectin-1.       Biochem. Biophys. Res. Commun.     
  364  :  959    –    965  .   
        18  .   Kissenpfennig  ,   A.  ,   S.     Henri  ,   B.     Dubois  ,   C.     Laplace-Builhe  ,   P.     Perrin  , 
  N.     Romani  ,   C.H.     Tripp  ,   P.     Douillard  ,   L.     Leserman  ,   D.     Kaiserlian  , 
  et al  .   2005  .   Dynamics and function of Langerhans cells in vivo: dermal 
dendritic cells colonize lymph node areas distinct from slower migrating 
Langerhans cells.       Immunity      .     22  :  643    –    654  .    
        19  .   Gonzalez  ,   S.  ,   V.     Groh  , and   T.     Spies  .   2006  .   Immunobiology of human 
NKG2D and its ligands.       Curr. Top. Microbiol. Immunol.       298  :  121    –    138  .    
        20  .   Raulet  ,   D.H.     2003  .   Roles of the NKG2D immunoreceptor and its li-
gands.       Nat. Rev. Immunol.       3  :  781    –    790  .    
        21  .   Lanier  ,   L.L.     2008  .   Up on the tightrope: natural killer cell activation and 
inhibition.       Nat. Immunol.       9  :  495    –    502  .    
        22  .   Moretta  ,   A.  ,   C.     Bottino  ,   M.     Vitale  ,   D.     Pende  ,   C.     Cantoni  ,   M.C.   
  Mingari  ,   R.     Biassoni  , and   L.     Moretta  .   2001  .   Activating receptors and 
coreceptors involved in human natural killer cell-mediated cytolysis.   
    Annu. Rev. Immunol.       19  :  197    –    223  .    
        23  .   Diefenbach  ,   A.  ,   A.M.     Jamieson  ,   S.D.     Liu  ,   N.     Shastri  , and   D.H.     Raulet  . 
  2000  .   Ligands for the murine NKG2D receptor: expression by tu-
mor cells and activation of NK cells and macrophages.       Nat. Immunol.     
  1  :  119    –    126  .    
        24  .   Cerwenka  ,   A.  ,   A.B.     Bakker  ,   T.     McClanahan  ,   J.     Wagner  ,   J.     Wu  ,   J.H.   
  Phillips  , and   L.L.     Lanier  .   2000  .   Retinoic acid early inducible genes 
defi  ne a ligand family for the activating NKG2D receptor in mice.   
    Immunity      .     12  :  721    –    727  .    
        25  .   Roberts  ,   A.I.  ,   L.     Lee  ,   E.     Schwarz  ,   V.     Groh  ,   T.     Spies  ,   E.C.     Ebert  , and 
  B.     Jabri  .   2001  .   NKG2D receptors induced by IL-15 costimulate CD28-
negative eff   ector CTL in the tissue microenvironment.       J. Immunol.     
  167  :  5527    –    5530  .   
        26  .   Das  ,   H.  ,   V.     Groh  ,   C.     Kuijl  ,   M.     Sugita  ,   C.T.     Morita  ,   T.     Spies  , and 
  J.F.     Bukowski  .   2001  .   MICA engagement by human Vgamma2Vdelta2 
T cells enhances their antigen-dependent eff  ector function.       Immunity      .   
  15  :  83    –    93  .    
        27  .   Girardi  ,   M.  ,   D.E.     Oppenheim  ,   C.R.     Steele  ,   J.M.     Lewis  ,   E.     Glusac  ,   R.   
  Filler  ,   P.     Hobby  ,   B.     Sutton  ,   R.E.     Tigelaar  , and   A.C.     Hayday  .   2001  . 
  Regulation of cutaneous malignancy by gammadelta T cells.       Science      .   
  294  :  605    –    609  .    
        28  .   Todd  ,   J.A.  ,   N.M.     Walker  ,   J.D.     Cooper  ,   D.J.     Smyth  ,   K.     Downes  ,   V.   
  Plagnol  ,   R.     Bailey  ,   S.     Nejentsev  ,   S.F.     Field  ,   F.     Payne  ,   et al  .   2007  . 
  Robust associations of four new chromosome regions from genome-
wide analyses of type 1 diabetes.       Nat. Genet.       39  :  857    –    864  .    
        29  .   Tomasec  ,   P.  ,   E.C.     Wang  ,   A.J.     Davison  ,   B.     Vojtesek  ,   M.     Armstrong  , 
  C.     Griffin  ,   B.P.     McSharry  ,   R.J.     Morris  ,   S.     Llewellyn-Lacey  ,   C.   
  Rickards  ,   et al  .   2005  .   Downregulation of natural killer cell-activat-
ing ligand CD155 by human cytomegalovirus UL141.       Nat. Immunol.     
  6  :  181    –    188  .    
        30  .   Baury  ,   B.  ,   D.     Masson  ,   B.M.     McDermott     Jr  .,   A.     Jarry  ,   H.M.     Blottiere  , 
  P.     Blanchardie  ,   C.L.     Laboisse  ,   P.     Lustenberger  ,   V.R.     Racaniello  , and 
  M.G.     Denis  .   2003  .   Identifi  cation of secreted CD155 isoforms.       Biochem. 
Biophys. Res. Commun.       309  :  175    –    182  .                  